-
Regenerative Medicine - Uncorrected Evidence (15th January 2013) (
)Published 28 January 2013Alastair Kent, Director, Genetic Alliance UK, Dr Chris Bravery, Principal Consultant, Consulting on Advanced Biologicals (CAB) Ltd, and Dr Julian Braybrook, Director of Strategy, Measurement Research, LGC
-
Regenerative Medicine Uncorrected Evidence (08 January 2013) ()Published 14 January 2013
Peter Thompson, Chief Executive Officer, Human Fertilisation and Embryology Authority (HFEA), and Dr Alan Clamp, Chief Executive Officer, Human Tissue Authority (HTA)
-
Regenerative Medicine - Uncorrected Evidence (08 January 2013) ()Published 14 January 2013
Professor Sir Kent Woods, Chief Executive, Medical and Healthcare products Regulation Agency, Dr Hans-Georg Eichler, Senior Medical Office, European Medicine Agency, and Dr Janet Wisely, Chief Executive, Health Research Agency
-
Regenerative Medicine Uncorrected Evidence (18 December 2012) ()Published 07 January 2013
Keith Thompson, Chief Executive Officer, Cell Therapy Catapult Centre; and Dr Zahid Latif, Head of Healthcare, Technology Strategy Board
-
Regenerative Medicine - Uncorrected Evidence (18 December 2012) ()Published 07 January 2013
Professor David Williams, Director, EPSRC Centre for Innovative Manufacturing in Regenerative Medicine, Loughborough University; Keith Thompson, Chief Executive Officer, Cell Therapy Catapult Centre; and Dr David Newble, Chief Executive Officer, TAP Biosystems
-
Regenerative Medicine Uncorrected Evidence (11 December 2012) ()Published 19 December 2012
Aidan Courtney, Chief Executive Officer, Roslin Cells Limited, Professor Marc Turner, Medical Director, Scottish National Blood Transfusion Service, and Dr Glyn Stacey, Director, UK Stem Cell Bank
-
Regenerative Medicine Uncorrected Evidence (11 December 2012) ()Published 19 December 2012
Professor Carole Longson, Director, Centre for Health Technology Evaluation, NICE, Dr Guido Schopen, Vice-President Commercial Operations, TiGenix NV, and Dr Natalie-Jane MacDonald, Managing Director, Bupa Health and Wellbeing UK
-
Regenerative Medicine - Uncorrected Evidence (20 November 2012) ()Published 27 November 2012
Dr Ruth McKernan, Chief Scientific Officer of the Neusentis Unit, Pfizer, Professor Chris Mason, Professor of Regenerative Medicine Bioprocessing, University College London, and Michael Hunt, Chief Executive Officer, ReNeuron
-
Regenerative Medicine - Uncorrected Evidence (20 November 2012) ()Published 27 November 2012
Dr Navid Malik, Head of Life Sciences Research, Cenkos Securities plc, Dr Nigel Pitchford, Managing Director of Healthcare, Imperial Innovations, and Dr Steven Dyson, Partner, Healthcare team, Apax Partners
-
Regenerative Medicine Uncorrected Evidence (30 October 2012) ()Published 07 November 2012
Professor Peng Tee Khaw, Moorfields Eye Hospital, University College London, Professor Roger Barker, University of Cambridge, and Professor Michael Schneider, National Heart and Lung Institute, Imperial College London
-
Public Procurement as a Tool to Stimulate Innovation - Uncorrected Evidence (16 October 2012 ()Published 25 October 2012
Rt Hon David Willetts MP, Minister of State for Universities and Science, Department for Business, Innovation and Skills, Norman Baker MP, Parliamentary Under-Secretary of State, Department for Transport, and Rt Hon Francis Maude MP, Minister for the Cabinet Office